BCRX vs BMRN
BCRX: BioCryst Pharmaceuticals is a biotech company focused on commercializing and developing innovative therapies for hereditary angioedema and other rare diseases using structure-guided drug design. BMRN: BioMarin is a biotechnology leader dedicated to transforming the lives of patients with rare, genetically defined diseases through innovative, category-defining medicines.
Side-by-side fundamentals
| Metric | BCRX | BMRN | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $9.38 | $63.81 | |
| Market cap as of 2026-08-09 | $2.4B | $12.4B | |
| P/E as of 2026-08-09 | 9.08 | 45.89 | BCRX lower |
| PEG as of 2026-08-09 | -0.01 | 0.67 | BCRX lower |
| Net margin as of 2026-08-09 | -51.7% | +8.3% | BMRN higher |
| Gross margin as of 2026-08-09 | +97.8% | +80.2% | BCRX higher |
| Operating margin as of 2026-08-09 | -45.1% | +9.7% | BMRN higher |
| ROE as of 2026-08-09 | -328.8% | +4.4% | BMRN higher |
| ROA as of 2026-08-09 | -97.3% | +3.4% | BMRN higher |
| Debt / equity as of 2026-08-09 | 2.26 | 0.23 | BMRN lower |
| Revenue growth (YoY) as of 2026-08-09 | +75.9% | +9.9% | BCRX higher |
| Revenue CAGR (3y) SEC XBRL | +22.8% | +15.4% | BCRX higher |
| Beta as of 2026-08-09 | 0.55 | 0.21 | |
| 1-year return as of 2026-08-07 close | +12.3% | +7.3% | BCRX higher |
Fundamentals: market data, as of 2026-08-09. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.